Cadila Healthcare
Cadila Healthcare News
Indian drug regulator allows Cadila Healthcare to conduct phase III trials for two-dose COVID-19 vaccine
The company has already received the emergency use authorization from the Drug Controller General of India (DCGI) for ZyCoV-D to be administered in three doses
Zydus Cadila launches insomnia drug in US market; company's shares trade 1.48% lower at Rs 232.20
The Gujarat-based Zydus Cadila has more than 270 USFDA approvals and has filed over 360 abbreviated new drug applications (ANDAs), since it commenced filings in 2003-04
Zydus Cadila gets USFDA nod to market generic anti-diabetic drug
Drug firm Zydus Cadila Thursday said it has received tentative nod from the US health regulator to market generic Sitagliptin and Metformin Hydrochloride extended-release tablets used for controlling blood sugar levels
Zydus Cadila gets USFDA nod to market blood pressure lowering drug in the US
Drug firm Zydus Cadila on Tuesday said it has received final approval from the US health regulator to market Atenolol and Chlorthalidone tablets USP, used to treat high blood pressure, in the US
Cadila Healthcare, Zydus Wellness to buy Heinz India for Rs 4,595 cr; Complan, Glucon D, Nycil brands part of deal
The transaction is proposed to be financed by a mix of equity and debt
Zydus Group clinches in-licensing deal with Swiss co Neovii to market Grafalon drug
Grafalon offers a specific advantage of efficacy and better safety profile through targeted immunosuppression
Cadila Healthcare gets EIR for Ahmedabad plant from USFDA
The EIR report is given to an establishment after the completion of an inspection by the USFDA
Cadila Healthcare Q1 net dips 23% to Rs 356 crore
Consolidated total income from operations of the company stood at Rs 2,287.1 crore for the quarter
Warning letters for pharma cos galore: Now Cadila Healthcare faces USFDA heat, stock tanks 16%
The Ahmedabad-headquartered company received a warning letter for its Moraiya formulation facility and Ahmedabad API facility
Cadila Healthcare Q3 profit rises 52% to Rs 282 cr
Drug firm Cadila Healthcare reported a 52 percent rise in its consolidated net profit to Rs 281.91 crore for the third quarter ended 31 December 2014 on back of robust sales.
Zydus gets FDA tentative nod to market anti-diabetic tablets in US
According to IMS health the estimated sales in 2014 for Glipizide ER tablets is $90.1 million
Cadila gains 4% as US FDA revokes warning on unit
The warning was issued in June 2011, saying the facilities in the plant were not conforming to the US FDA guidelines and that there were fears the company's drugs from the unit may get adulterated.
Broker Alert: Dump Voltas, Exide has the right mix
Voltas' cooling division is facing increased pressure on the margin front as other players are offering freebies and discounts to liquidate existing inventories.